Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients - Association between non-responders and chronic kidney disease

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 397-404

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Shiga, Taro ^a   Kato, Naoko ^a   Muraoka, Hironori ^a   Minatsuki, Shun ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Kyo, Shunei ^a   Nagai, Ryozo ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Nephrogenic diabetes insipidus; Renal dysfunction; Vasopressin

Indexed keywords

ALBUMIN; ARGIPRESSIN; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; POTASSIUM ION; SODIUM ION; TOLVAPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; URINE OSMOLALITY; URINE VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; BLOOD UREA NITROGEN; CREATINE; DIABETES INSIPIDUS, NEPHROGENIC; DIURETICS; DRUG MONITORING; FEMALE; HEART FAILURE; HUMANS; HYPOVOLEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; POTASSIUM; PREDICTIVE VALUE OF TESTS; RECEPTORS, VASOPRESSIN; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY; SODIUM; URINE; YOUNG ADULT;

EID: 84873806179     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0971     Document Type: Article

References (31)

1. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46: 1785-1791.
2. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994; 128: 564-574.
3. Tada Y, Nakamura T, Funayama H, Sugawara Y, Ako J, Ishikawa SE, et al. Early development of hyponatremia implicates short- and longterm outcomes in ST-elevation acute myocardial infarction. Circ J 2011; 75: 1927-1933.
4. Greenberg B. Acute decompensated heart failure: Treatments and challenges. Circ J 2012; 76: 532-543.
5. Kinugawa K. How to treat stage D heart failure?: When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
6. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25(Suppl 1): S33-S45.
7. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
8. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
9. Hori M. Tolvaptan for heart failure patients with volume overload. Cardiovasc Drugs Ther 2011; 25(Suppl 1): S1-S4.
10. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545.
11. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
12. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-161.
13. Purssell RA, Pudek M, Brubacher J, Abu-Laban RB. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. Ann Emerg Med 2001; 38: 653-659.
14. Mayinger B, Hensen J. Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes 1999; 107: 157-165.
15. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867.
16. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008; 371: 1624-1632.
17. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-F278.
18. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25(Suppl 1): S57-S65.
19. Wong NL, Tsui JK. Angiotensin II upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. Metabolism 2003; 52: 290-295.
20. Kwon TH, Frokiaer J, Knepper MA, Nielsen S. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 1998; 275: F724-F741.
21. Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail 2012; 5: 484-492.
22. Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int 2003; 63: 1417-1425.
23. De Wardener HE, Del Greco F. The influence of solute excretion rate on the production of a hypotonic urine in man. Clin Sci (Lond) 1955; 14: 715-723.
24. Bichet DG, Oksche A, Rosenthal W. Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8: 1951-1958.
25. Jozwiak L, Jaroszynski A, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A. Pseudo-Bartter syndrome: 2 cases. Przegl Lek 2010; 67: 222-224 (in Polish).
26. Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure: Evidence for the role of decreased V2 receptor mRNA. J Clin Invest 1995; 96: 378-385.
27. Bedford JJ, Leader JP, Walker RJ. Aquaporin expression in normal human kidney and in renal disease. J Am Soc Nephrol 2003; 14: 2581-2587.
28. Kleeman CR, Adams DA, Maxwell MH. An evaluation of maximal water diuresis in chronic renal disease. I: Normal solute intake. J Lab Clin Med 1961; 58: 169-184.
29. Kamel KS, Ethier JH, Richardson RM, Bear RA, Halperin ML. Urine electrolytes and osmolality: When and how to use them. Am J Nephrol 1990; 10: 89-102.
30. Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, et al. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol 2011; 6: 753-759.
31. + channel (ENaC) by vasopressin in adrenalectomized mice. Proc Natl Acad Sci USA 2012; 109: 10095-10100.